Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2014-08-12 Regulatory Filings
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
Synergy of SCIB1 with checkpoint inhibitors
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's Regulatory News Service (RNS). The content is a press release announcing new scientific data regarding the synergy of their drug candidate (SCIB1) with checkpoint inhibitors. This is a general corporate update/announcement that does not fit the specific definitions for Earnings Release (ER), Interim Report (IR), Annual Report (10-K), or a specific transaction like Director's Dealing (DIRS) or Capital Change (SHA). Since it is a general regulatory announcement disseminated through the official channel (RNS), and it is not a report itself (it's an announcement of data), the most appropriate classification is Regulatory Filings (RNS), which serves as the general regulatory announcement category.
2014-08-12 English
Director/PDMR Shareholding
Remuneration Information Classification · 99% confidence The document is identified by the 'RNS Number' header and the concluding statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content explicitly announces the 'Grant of Options to Director' (Dr Sally Adams) under a share option scheme, detailing the number of options, vesting period, and exercise price. This type of insider transaction reporting, specifically concerning director dealings or option grants to directors, falls under the category of Director's Dealing (DIRS). Although it is an RNS announcement, DIRS is a more specific classification than the general RNS fallback.
2014-06-19 English
DNA ImmunoBody Patent Granted in United States
Regulatory Filings Classification · 98% confidence The document is identified by the 'RNS Number : 9796I' header and the concluding statement 'This information is provided by RNS The company news service from the London Stock Exchange'. This indicates it is a regulatory announcement. The content announces a specific corporate event: the granting of a patent in the United States for their DNA ImmunoBody® technology. This type of announcement, which is a general regulatory update that doesn't fit into specific categories like earnings (ER), director dealings (DIRS), or capital changes (CAP), is best classified under the general regulatory filing category, RNS, as per the definitions and the explicit RNS tagging.
2014-06-06 English
Update on Phase 1/2 trial of SCIB1 in melanoma
Regulatory Filings Classification · 98% confidence The document is identified by the presence of an 'RNS Number' and the closing statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content details an 'Update on Phase 1/2 clinical trial of SCIB1' including clinical results, safety data, and commentary from CEOs and investigators. This is a substantive announcement of clinical trial results, which typically falls under a general regulatory announcement category if a more specific one like 'ER' (Earnings Release) or 'LTR' (Legal Proceedings Report) does not apply. Since it is a detailed update on clinical progress and not a formal, comprehensive financial report (like 10-K or IR), and it is explicitly flagged as an RNS release, the most appropriate classification is the general regulatory filing category, RNS, as it is a broad announcement of material information.
2014-06-02 English
Presents latest SCIB1 data at ASCO
Regulatory Filings Classification · 99% confidence The document is identified by the 'RNS Number' header and the closing statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content announces that Scancell Holdings Plc will present clinical trial data at the ASCO Annual Meeting. This is a general regulatory announcement concerning company activity (a presentation of scientific data) that does not fit into the specific categories like Earnings Release (ER), Interim Report (IR), or Director's Dealing (DIRS). Given its nature as a standard, non-specific regulatory update distributed via the RNS service, the most appropriate classification is the general Regulatory Filings category (RNS). The document length (3266 chars) is short, but it is not announcing the publication of a major report, but rather an event/presentation, making RNS more suitable than RPA.
2014-05-15 English
Directorate Change
Board/Management Information Classification · 98% confidence The document is very short (2094 characters) and is explicitly marked with an 'RNS Number' and contains the header 'Scancell Holdings Plc Directorate Change'. The content announces that Mr. Peter Allen is stepping down as a non-executive Director as of the date of the announcement (09 May 2014). This directly relates to a change in the company's board of directors or senior management. This matches the definition for Board/Management Information (MANG). Although it is distributed via RNS, the specific content dictates the MANG classification over the general RNS fallback.
2014-05-09 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.